COMPARISON
Chartink vs Screener.in: which is better? (October 2026)
Chartink vs Screener.in compared on price, free plan, refunds, technical and fundamental scans, alerts, backtests and apps, with a pick for each trader.
Chartink is the better pick for technical traders, because its free scan builder covers price, volume, indicators and intraday timeframes from 5 minutes. Screener.in is the better pick for fundamental investors, because its free query screens run on ten years of financial data.
How do Chartink and Screener.in compare?
| Chartink | Screener.in | |
|---|---|---|
| Built for | Technical and intraday scans | Fundamental screens |
| Paid price | ₹780 for 30 days, ₹2,220 for 90 days, ₹8,500 a year (tax incl.) | ₹4,999 a year (GST incl.); no monthly plan |
| Free plan | Scans and charts; intraday from 5 minutes; delayed data | Query screens, 18 quick ratios, 10 stock alerts, 2 screen alerts |
| Free trial | No | No |
| Refund | None once activated | Full refund within 48 hours |
| Technical scans | Indicators, custom indicators, 1 minute to monthly | DMA and RSI screens |
| Fundamental screens | About 40 fields (2017 post) | Own queries on 10 years of data |
| Alerts | Premium only: SMS, email, webhook | 10 stock and 2 screen alerts free; 800 and 75 on Premium |
| Backtests | Matches over time; up to 9 years daily | Not found |
| Public screens | 1,50,000+ (its own figure) | 10,000+ user screens |
| AI | Not found | Screener AI, about ₹10 to ₹30 per answer |
| App | Web only | Android 4.3★ from 3,898 ratings; no iOS app |
Prices and limits checked on each vendor's own pages on 25 October 2026.
Which should you choose?
- Swing or intraday trader: Chartink. Free technical scans, candlestick and Heikin-Ashi charts, and price history back to 1980.
- Long-term fundamental investor: Screener.in. Free custom queries on ten years of statements and 12 annual years on company pages.
- Trader who wants alerts on a breakout: Chartink Premium. Scan alerts run as often as every minute and can post to a webhook.
- Investor on a tight budget: either free plan. Both are useful without paying.
What are Chartink's pros and cons?
Pros
- Build your own scans with custom indicators and mathematical functions.
- Intraday timeframes from 5 minutes on the free plan.
- Backtest results for every scan, up to 9 years on daily scans.
- Alerts by SMS, email or webhook on Premium.
Cons
- Free scans show delayed data; real-time scans need Premium.
- No refunds once the plan is active, and no trial.
- Backtests show matching stocks, not strategy returns, and use today's fundamental values.
- Web only; no mobile app.
What are Screener.in's pros and cons?
Pros
- Free query screens on ten years of financial data.
- 10,000+ user screens to copy.
- Full refund within 48 hours on Premium.
- Excel export; custom Excel templates on Premium.
Cons
- Few technical filters (DMA and RSI screens exist).
- Premium is annual only.
- Screener AI is billed per answer once Premium's ₹500 of credits is used.
- Android app only; no iOS app found.
How do you use them together?
- Write a quality screen on Screener.in, for example on return on capital and debt.
- Save the matches as a watchlist on Chartink, then scan that watchlist for breakouts. Scanning a watchlist through the segment menu is a Premium benefit on Chartink.
- We found no import between them. Re-enter symbols by hand or by watchlist upload on Chartink.
For more technical scanners, see Chartink alternatives and the best stock screener for swing trading.
Related comparisons
Figures were checked on 25 October 2026. Email support@tapetide.com if any are out of date. This page is for information only and is not investment advice.
Questions people ask
Which is better, Chartink or Screener.in?
Is Chartink free?
How much does Chartink Premium cost?
How much does Screener.in Premium cost?
Does either offer a refund?
Can I screen fundamentals on Chartink?
Can I run technical screens on Screener.in?
Which has backtesting?
Does Chartink or Screener.in have a mobile app?
Can I use both together?
Tapetide provides research data and tools. Nothing on this page is investment advice.